Active — Not RecruitingPhase 1

A Study in Healthy People to Test How Vicadrostat Affects the Heart

Germany45 participantsStarted 2026-04-22

Plain-language summary

The main objective of this trial is to investigate the effect of vicadrostat on the heart compared with placebo in healthy male and female volunteers.

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Healthy male or female trial participant according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests
✓. Age of 18 to 50 years (inclusive)
✓. Body mass index (BMI) of 18.5 to 29.9 kg/m² (inclusive)
✓. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial Further inclusion criteria apply.

Exclusion criteria

✕. Any finding in the medical examination (including BP, PR or ECG deviating from normal and assessed as clinically relevant by the investigator
✕. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
✕. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
✕. Any evidence of a concomitant disease assessed as clinically relevant by the investigator Further exclusion criteria apply.

What they're measuring

The maximum mean difference between each single dose of either low or high dose of vicadrostat and placebo in QTcF changes from baseline between 20 min to 24 hours after drug administration

Timeframe: at baseline, up to 24 hours

Trial details

NCT IDNCT07513207

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-07-24

View on ClinicalTrials.gov More Healthy trials